Compare Novo Nordisk A/S (NVO) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Global X Robo Global Robotics & Automation ETF — how do they compare? Novo Nordisk A/S trades at $45.01 (market cap $198.57B), while Global X Robo Global Robotics & Automation ETF trades at $79.45. The key difference: Novo Nordisk A/S pays a 4.03% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | ROBO | |
|---|---|---|
Market Cap | $198.57B | — |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $90.34 |
52-Week Low | $35.29 | $63.04 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
ROBO Global Robotics and Automation Index ETF trades at $79.65, down 1.14% over 24 hours, with technical indicators showing a bearish trend. The ETF provides diversified exposure to robotics and AI, with recent news highlighting accelerating adoption in manufacturing and military applications. Key support is at $80, with resistance at $81, while moving averages signal selling pressure.
The outlook for ROBO is supported by long-term growth in robotics adoption, but near-term risks include market volatility and high valuations. Investment opportunity lies in sector diversification, though investors face headwinds from economic cycles and competitive ETF offerings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
